Status: Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Participants needed: 12
Trial details
Phase: Phase 2Age: 12-17Biological sex: AllType: InterventionalSponsor: Apellis Pharmaceuticals, Inc.Updated: Jun 26, 2026Locations: 12
Eligibility criteria
Are 12-17 years old at the time of screening [+5]
Are an adult, 18 years of age or older, with PNH [+3]